One of my favorite types of papers are those on stem cells and chromatin, and a new one in Current Biology caught my eye this week. My own lab website has the URL chromatin.com so that says something. You can also read more about our research here. Recommended reads: chromatin and stem cells, more Asymmetric […]
Weekly recommended reads including asymmetric division & chromatin Read More »
For more than a year in my first job as a scientist I isolated cells from umbilical cord veins and then tossed the tissue away, never realizing there was more there that could be useful in the form of something called Wharton’s jelly. What’s in this article Umbilical cord histology & Wharton’s jelly | What
What is Wharton’s jelly & its possible clinical uses? Read More »
What can a gecko possibly teach us about skin cancer? Read on. It’s fun when a week’s worth of science reading covers so much territory including COVID-19, geckos that get cancer, a research misconduct sleuth, an FDA letter, and more. Baltimore weighs in on COVID lab origin idea Caltech has a very interesting interview with
Recommended reads: Bik, FDA letter, gecko cancer model, David Baltimore on COVID origin Read More »
ViaCyte released encouraging data just now on a patient with implanted stem cell-derived pancreas-like device whose diabetes improved. You can read more about this in the Endpoints piece that I linked to in the previous sentence. Stem cells for diabetes; the ViaCyte update The idea of stem cells for diabetes has been more on my
Quick reaction to milestone ViaCyte data on a diabetes patient Read More »
Although in my years as a stem cell biologist I haven’t yet been in a leadership role at the International Society for Stem Cell Research or ISSCR, unproven stem cell clinics have claimed that I somehow speak for ISSCR. I am just a standard member of the group like thousands of other researchers. In fact,
Recommended reads: ISSCR guidelines pushback, TB outbreak from regen product, pubs Read More »
After the COVID-19 pandemic started clinical trials quickly sprouted up to test various kinds of cell therapy for COVID-19 including stem cells. The most common rationale for this approach is to suppress damaging overactive immune responses. Trials of cell therapy for COVID-19 including stem cells I’ve written quite a lot about these cellular medicine and
Our new paper assessing trials of cell therapy for COVID-19 Read More »
Professor Joanne Kurtzberg’s clinical work at the Duke Autism Center on umbilical cord blood for autism and cerebral palsy (CP) involves a partnership with a publicly-traded cord blood banking firm called Cryo-Cell. Kurtzberg is also the Medical Director at the firm. In addition they have intellectual property in this area. The Duke team’s efforts, including
Duke & Cryo-Cell plan big clinic for unproven infusions of kids Read More »
My to-read list this weekend includes a range of papers along with various news & media including a report of two US research groups aiming to get CRISPR baby patents. More on that below. At long last a trip + fun thing to do in NYC Last week I took my first trip in more
Weekly reads: escape to New York, CRISPR baby patents, ISSCR guidelines, pubs Read More »
Something called the 14-day rule on growing human embryos in the lab helped keep a tough question in check for a long time: when is it ethically wrong or just practically unwise to continue growing a human embryo for research? There is no good answer based on science or anything else. ISSCR moves beyond strict
Risks rise as ISSCR drops strict 14-day rule on human embryo growth in the lab Read More »
Sometimes things in the stem cell world get complicated and this week is no exception with news of Orchard Therapeutics dropping a seemingly life-saving clinical trial. There are hundreds of kids who could possibly benefit. Rotten apple decision from Orchard Therapeutics From David Jensen at California Stem Cell Report we have something of a scoop:
Weekly reads: Orchard punts on life-saving SCID trial, cardioids with cavities, more Read More »